Christoph M.
- Country
- Germany
- Department
- 04908: Frauenklinik & Brustzentrum
Research Overview
- Phase 3 Randomized Study of Gedatolisib Combination Therapy versus Standard Endocrine Therapy in HR‑Positive, HER2‑Negative Advanced Breast Cancer Post‑CDK4/6 Inhibitor
- Evaluation of Elacestrant and Olaparib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer with gBRCA1/2 Mutations
- Phase 3 Randomized Study of GLSI-100 (GP2 + Sargramostim) in HER2/neu Positive Breast Cancer with Residual Disease or High-Risk PCR Post-Trastuzumab Therapy
Data & Insights
Has run more than one trial at 65 of 267 partner sites.
Specializations
Breast Cancer Therapeutics
The investigator specializes in treating hormone receptor-positive breast cancer, with particular focus on developing therapeutic strategies for HER2-positive and HER2-negative variants.
- Advanced metastatic breast cancer management
- HER2/neu targeted therapies
- Hormone receptor-positive disease treatment
Advanced expertise in combination therapy approaches utilizing targeted agents and hormone-based treatments.
Precision Oncology
Focuses on developing personalized treatment approaches for patients with genetic mutations, particularly those with BRCA1/2 mutations in breast cancer.
- Selective estrogen receptor degraders (SERDs)
- Targeted molecular therapies
- Biomarker-driven treatment selection
Expertise in molecular profiling and targeted therapeutic interventions for specific genetic alterations.
Metastatic Disease Management
Specializes in treating brain metastases and other advanced manifestations of breast cancer, with emphasis on novel therapeutic combinations.
- Brain metastasis treatment strategies
- Innovative drug combinations
- Disease progression monitoring
Advanced experience in managing complex metastatic disease patterns and treatment resistance.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.